Skip to main content
. 2016 Jul 4;16:54. doi: 10.1186/s12935-016-0334-1

Table 2.

Univariate analysis of variables associated with 5-year OS and PFS (n = 424)

Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.528 0.129–0.849 0.008 0.541 0.136–0.894 0.002
HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA 0.404 0.025–0.647 0.001 0.529 0.151–0.826 0.001
Age : ≤46 versus >46 0.452 0.121–0.837 0.014 0.412 0.087–1.030 0.040
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA 0.197 0.018–0.416 0.034 0.484 0.0134–0.839 0.024
pathological type: SCC versus ADC versus ASC versus UDC 0.418 0.168–0.827 0.031 0.478 0.174–0.930 0.043
Lymph node status classification: positive lymph node versus negative lymph node 3.586 0.876–5.439 0.043 2.542 1.047–4.283 0.045
Treatment modality: IC + RT versus CCRT versus IC + CCRT 0.530 0.129–0.934 0.039 2.164 1.687–4.017 0.102
ALC: high versus low 0.571 0.292–0.843 0.002 0.513 0.385–0.738 0.008
AMC: high versus low 2.418 1.215–4.738 0.931 0.714 0.306–1.136 0.035

OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count